Semaglutide

An FDA-approved GLP-1 receptor agonist sold as finished products, including Ozempic, Wegovy, and Rybelsus. Large randomized trials support labelled uses in type 2 diabetes, chronic weight management, cardiovascular risk reduction, kidney outcomes in type 2 diabetes with CKD, and noncirrhotic MASH with moderate to advanced fibrosis on Wegovy. A compounded copy is not the labelled product.

A long-acting GLP-1 receptor agonist. Proposed effects include slower gastric emptying, glucose-dependent insulin secretion, glucagon suppression, and reduced appetite via central GLP-1 pathways. Those are labelled-product mechanisms, not a protocol.

STEP 1 (Wilding et al., 2021; PMID 33567185) assigned 1,961 adults with overweight or obesity and without diabetes to once-weekly subcutaneous semaglutide 2.4 mg or placebo for 68 weeks. Mean body-weight change was −14.9% versus −2.4%. SELECT (Lincoff et al., 2023; PMID 37952131) enrolled 17,604 adults with preexisting cardiovascular disease, BMI of 27 or greater, and no history of diabetes. The primary endpoint was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. At a mean follow-up of 39.8 months, a primary event occurred in 6.5% versus 8.0% (hazard ratio 0.80). FLOW (Perkovic et al., 2024; PMID 38785209) assigned 3,533 adults with type 2 diabetes and chronic kidney disease to once-weekly semaglutide 1.0 mg or placebo. The primary kidney composite occurred less often with semaglutide (hazard ratio 0.76). That is the labelled Ozempic kidney use, not a second obesity score. ESSENCE part 1 (Sanyal et al., 2025; PMID 40305708; NCT04822181) reported week-72 histology in the first 800 of 1,197 patients with biopsy-defined MASH and fibrosis stage 2 or 3 on once-weekly semaglutide 2.4 mg. Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% versus 34.3%; fibrosis improvement without worsening of steatohepatitis occurred in 36.8% versus 22.4%. That histology readout supports Wegovy’s accelerated MASH indication. It is not an extra weight-loss score.

FDA-approved finished products. Ozempic is labelled for type 2 diabetes, cardiovascular risk reduction in type 2 diabetes with established cardiovascular disease, and reduction of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and CKD. Wegovy is labelled for weight reduction, cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, and, under accelerated approval dated 15 August 2025, noncirrhotic MASH with moderate to advanced fibrosis (F2–F3). Rybelsus is an oral labelled product for specified type 2 diabetes uses. Insurance coverage, when it exists, attaches to a labelled product and a labelled use. Compounded copies are not the labelled product.

A licensed clinician writes a prescription for a specific approved product — Ozempic or Rybelsus for type 2 diabetes, Wegovy for chronic weight management — filled by a pharmacy. Compounded copies were a shortage-era workaround. After FDA declared the shortages resolved, compounding copies of these approved GLP-1s is generally not permitted except in narrow 503A/503B cases (a documented clinical difference that the approved product cannot meet).

Same four pathways as the Sourcing guide.

Ozempic is commonly covered for type 2 diabetes with prior authorization. Wegovy for obesity is a commercial-plan lottery: many require BMI thresholds plus a comorbidity, step therapy, or both. Medicare Part D has long covered incretins for diabetes and, for Wegovy, certain cardiovascular indications. Starting 1 July 2026, the Medicare GLP-1 Bridge covers Wegovy (injection or tablet) at $50 per month for eligible Part D members through 31 December 2027. Manufacturer savings cards may apply if you have commercial insurance; they usually do not stack with Medicare.

Counterfeit pens, compounded 'semaglutide sodium' or acetate, and research vials labeled not for human use. FDA has warned that some compounded products used salt forms that are not the approved drug, and that falsified Ozempic-like pens have entered the US supply. A Telegram listing is not a pharmacy.

Strand does not list vendors. See the grey market.

Gastrointestinal adverse events are common on the labels. Both Ozempic and Wegovy carry a boxed warning for thyroid C-cell tumors in rodents; human relevance is unknown. Both are contraindicated in personal or family history of MTC or in MEN 2. Both warn about gallbladder disease and pancreatitis. Pregnancy language is labelled and is not one sentence for every product or use. Wegovy’s label says discontinue when pregnancy is recognized for cardiovascular-risk-reduction and weight-reduction uses. For Wegovy’s MASH use, and for Ozempic, the labels say use during pregnancy only if the potential benefit justifies the potential risk to the fetus.

• Gastrointestinal effects are common and sometimes treatment-limiting.
• Gallbladder disease and a pancreatitis caution are on the labels.
• Boxed warning: rodent thyroid C-cell tumors; contraindicated in personal or family MTC or MEN2.
• Not for pregnancy. Lean-mass loss travels with fat-mass loss.
• Weight typically returns when the drug is stopped.
• Unregulated or compounded copies add identity, sterility, and dosing risk that the trials never measured.

• Wilding et al., STEP 1 · 2021 · N Engl J Med

  Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021. PMID 33567185. DOI 10.1056/NEJMoa2032183. n=1,961; 68 weeks; mean weight change −14.9% vs −2.4%. PMID 33567185.

• Lincoff et al., SELECT · 2023 · N Engl J Med

  Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023. PMID 37952131. DOI 10.1056/NEJMoa2307563. n=17,604; primary MACE HR 0.80. PMID 37952131.

• Perkovic et al., FLOW · 2024 · N Engl J Med

  Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024. PMID 38785209. DOI 10.1056/NEJMoa2403347. n=3,533; once-weekly 1.0 mg; kidney composite HR 0.76. Labelled Ozempic CKD use, not an obesity score. PMID 38785209.

• Sanyal et al., ESSENCE part 1 · 2025 · N Engl J Med

  Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025. PMID 40305708. DOI 10.1056/NEJMoa2413258. NCT04822181. Week-72 histology in the first 800 patients. Supports Wegovy’s accelerated MASH indication; not an extra obesity score. PMID 40305708.

• Ozempic (semaglutide) prescribing information

  DailyMed setid adec4fd2-6858-4c99-91d4-531f5f2a2d79. Labelled to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and CKD, in addition to glycemic and CV uses. Pregnancy: use only if the potential benefit justifies the potential risk to the fetus (DailyMed 8.1).

• Wegovy (semaglutide) prescribing information

  DailyMed setid ee06186f-2aa3-4990-a760-757579d8f77b. Weight and CV labelled uses. Accelerated-approval indication for noncirrhotic MASH with moderate to advanced fibrosis. Pregnancy language differs for the MASH use.

• FDA, Wegovy MASH accelerated approval

  FDA notice, 15 August 2025. Accelerated approval of Wegovy injection for noncirrhotic MASH with moderate to advanced fibrosis. Other labelled use, not an obesity score.